Heather McKenzie

Heather McKenzie

Senior Editor

Heather McKenzie is a professional journalist with more than 8 years’ experience in the biopharmaceutical industry. Since joining BioSpace, she has written more than 300 features and breaking news articles, including multiple award-winning stories. Her particular focuses are neuroscience, rare disease and regulatory science. She has also traveled internationally to cover global biotech hubs, including Israel. In previous roles, she has covered current affairs, sports, education and politics. She previously spent eight years as a senior content producer for executive-level business conferences in the pharma/biotech, legal, energy and business strategy sectors. In her free time, Heather enjoys creative writing, watching her American League champion Toronto Blue Jays, spending time with family and playing with her energetic Russian Blue cat Roofus. She hails from Toronto and has also lived in Chicago and Chesapeake, Virginia. You can reach her at heather.mckenzie@biospace.com.

Merck will acquire Acceleron for the expected $180 per share in cash for an approximate total equity value of $11.5 billion.
EDIT-101 targets a disease-causing mutation in the CEP290 gene that causes degeneration in ocular photoreceptor cells, which are critical for normal vision.
The announcement came following independent FDA analyses of inspections conducted at the two CROs in November 2019.
The news sparked a mini-surge in shares of I-Mab, which were up 7.8% in pre-market U.S trading on September 28.
Biomolecular condensates could hold the key to unlocking a number of neurological diseases that have baffled researchers the longest.
Anji will use the new funds to advance its two late-stage clinical programs in metabolic disorders and propel its oncology pipeline into the clinic.
Avanir is developing its future leadership from within through a program it calls “Leading at Avanir,” which focuses on emotional intelligence and situational leadership components.
The rumors had already been percolating as Acceleron’s stock has risen over the past 10 days from $130-a-share in mid-September to $167.65 as the market closed on Friday.
The analysis showed a 52-week glucose remission rate of 65.2% among the 69 patients being followed.
Capricor announced positive final data from the HOPE-2 trial of its drug candidate. It showed a slowing of disease progression in Duchenne muscular dystrophy patients.
September 24 is World Cancer Research Day, a time for patients, caregivers and companies on the forefront of cancer R&D to look back and look ahead.
Cassava Sciences announced top-line results Wednesday from a 12-month interim analysis of its Alzheimer’s drug candidate simufilam.
Codagenix Inc. announced positive safety and immunogenicity data from a Phase I dose-escalation trial of its single-dose intranasal COVI-VAC vaccine.
Triumvira’s inaugural program is directed against HER2, a well-known tumor-associated antigen that is expressed in multiple tumors.
French artificial heart maker Carmat announced Tuesday that it had successfully implanted its Aeson artificial heart into the chest cavity of a 57-year-old woman.